|
|
||||||||

*
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, and
Division of Developmental and Clinical Immunology, Department of Microbiology, University of Alabama, Birmingham, AL 35294
| Abstract |
|---|
|
|
|---|
, class II ligation leads to the activation of protein
tyrosine kinases, including Lyn and Syk and subsequent phospholipase
C
-dependent mobilization of Ca2+. In this study,
experiments demonstrated reciprocal desensitization of class II and BCR
signaling upon cross-linking of either receptor, suggesting that the
two receptors transduce signals via common processes and/or effector
proteins. Because class II and BCR signal transduction pathways exhibit
functional similarities, additional studies were conducted to evaluate
whether class II signaling is regulated by BCR coreceptors. Upon
cross-linking of class II, the BCR coreceptors CD19 and CD22 were
inducibly phosphorylated on tyrosine residues. Phosphorylation of CD22
was associated with increased recruitment and binding of the protein
tyrosine phosphatase SHP-1. Similarly, tyrosine phosphorylation of CD19
resulted in recruitment and binding of Vav and phosphatidylinositol
3-kinase. Finally, co-cross-linking studies demonstrated that signaling
via class II was either attenuated (CD22/SHP-1) or enhanced (CD19/Vav
and phosphatidylinositol 3-kinase), depending on the coreceptor that
was brought into close proximity. Collectively, these results suggest
that CD19 and CD22 modulate class II signaling in a manner similar to
that for the BCR. | Introduction |
|---|
|
|
|---|
Ligation of class II has clearly been shown to exert a significant
effect on the biology of B cells through the activation of two distinct
signal transduction pathways. In quiescent murine B cells,
cross-linking of class II causes an elevation of cAMP and subsequent
translocation of protein kinase C (PKC) to the nucleus
(18, 19, 20, 21, 22). Alternatively, in murine B cells that have been
primed by stimulation through the B cell Ag receptor (BCR) and IL-4
receptor, cross-linking of class II has been shown to up-regulate the
activity of the Src family protein tyrosine kinase (PTK) Lyn and the
non-Src family PTK Syk (23, 24, 25). Together, these PTKs
mediate activation of phospholipase C
(PLC
), leading to the
production of inositol 1,4,5-trisphosphate (IP3)
and diacylglycerol, which mediate Ca2+
mobilization and activation of PKC, respectively (23, 24, 25).
In human B cells, ligation of class II mediates the activation of both
pathways as well (26, 27, 28, 29); however, the ability of class
II to couple to the PTK-dependent signaling pathway does not appear to
require prior activation of the cells (26, 27, 28, 29). Thus, it
is apparent that class II signaling is mediated by many of the same
effector proteins that are involved in BCR-dependent signal
transduction. Furthermore, recent studies have demonstrated that class
II-dependent activation of the PTK signaling pathway is regulated by
CD45 in a manner similar to that observed in BCR-dependent signaling
(24).
Additional similarities exist between class II- and BCR-mediated signal
transduction with regard to the structural requirements for coupling to
downstream PTKs. Studies have demonstrated that the ability of class II
to mediate PTK activation is dependent on motifs contained within the
transmembrane/extracellular region of the
- and/or
-chains of the
molecule (1, 25, 28, 29, 30, 31). Thus, it has been hypothesized
that class II, like the BCR, relies on interactions with other
transmembrane proteins to form a competent signal transducing complex.
Recent studies have shown that the ability of class II to activate PTKs
is dependent on its recruitment to membrane rafts (32).
Presumably, class II recruitment to membrane rafts results in its
localization to specific microdomains in the plasma membrane that are
enriched in Src family PTKs, and which contain one or more intermediate
transducer proteins that mediate class II signal transduction.
Because class II and BCR signaling pathways share numerous
similarities, studies were conducted to determine whether class II
signaling is subject to regulation by coreceptors in a manner similar
to that for the BCR. CD19 and CD22 are coreceptors that have been shown
to modulate signal transduction via the BCR (33, 34) and
were therefore chosen as candidates that might regulate class II
signaling. CD19 is a member of a multimeric complex comprised of CD21,
CD81, and Leu-13 and has been shown to enhance signaling via the BCR
(35, 36, 37, 38). Tyrosine phosphorylation of the cytoplasmic
domain of CD19 generates phosphotyrosine motifs that recruit Vav and
phosphatidylinositol 3-kinase (PI 3-K), as well as other effector
proteins (39, 40, 41). CD22 is a B cell-restricted, 140-kDa
glycosylated transmembrane protein that is inducibly phosphorylated on
tyrosine in response to BCR ligation. Phosphorylation of CD22 mediates
the recruitment of several effector proteins including PLC
, PI 3-K,
Syk, and the protein tyrosine phosphatase (PTP) SHP-1
(42, 43, 44). Recruitment and activation of SHP-1 by CD22 has
been demonstrated to attenuate signal transduction through the BCR
(45, 46, 47).
In this study, CD19 and CD22 were observed to become tyrosine phosphorylated following class II ligation, resulting in the recruitment of specific effector proteins. As a result, signaling was influenced either negatively (CD22/SHP-1) or positively (CD19/Vav and PI 3-K) when class II was coligated with these coreceptors. Collectively, the results obtained suggest that CD19 and CD22 can modulate class II- and BCR-dependent signaling in a similar manner.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). All experiments were performed using mice between the ages of 6 and 8 wk.
Biological reagents
The mAbs used in these studies were: D3.137.1 (rat IgG2a,
anti-mouse MHC class II, Iad,b haplotype),
Bet-2 (rat anti-mouse µ heavy chain), B76 (rat IgG1,
anti-mouse µ heavy chain), RG7/9.1 (mouse IgG2b, anti-rat
light chain), and CY34.1 (mouse IgG1, anti-mouse CD22). The mAbs
were purified using protein G-Sepharose 4B fast flow beads (Amersham
Pharmacia Biotech) and were biotinylated using
N-hydroxy-succinimidobiotin (Sigma, St. Louis, MO) as
described previously (48). The Abs PTP1C (mouse IgG1,
anti-SHP-1; Transduction Laboratories, Lexington, KY), 1D3 (rat
IgG2a, anti-mouse CD19; PharMingen, San Diego, CA), PE-conjugated
CY34.1 (mouse IgG1, anti-mouse CD22.2; PharMingen), anti-Vav
(mouse anti-human Vav; Upstate Biotechnology, Lake Placid, NY),
anti-PI 3-K (mouse IgG1, anti-human PI 3-K; Transduction
Laboratories), anti-IgG/A/M (F(ab')2 goat
anti-mouse IgG, IgA, IgM; Organon Teknicka, West Chester, PA), and
4G10 coupled to HRP (mouse IgG2b, anti-phosphotyrosine; Upstate
Biotechnology) were purchased for these studies. Dr. Robert Carter
(Department of Medicine, University of Alabama at Birmingham,
Birmingham, AL), generously provided mouse anti-CD19 cytoplasmic
domain mAb. The secondary Abs used in these studies included goat
anti-mouse IgG coupled to HRP and goat anti-rabbit IgG coupled
to HRP (Biosource International, Camarillo, CA). Additional reagents
used in these studies included NeutrAvidin (Pierce, Rockport, IL) and
streptavidin conjugated with PE (Biosource International). Mouse IL-4
was purchased from R&D Systems (Minneapolis, MN).
Splenic B cells and cell lines
Resting splenic B cell were purified as previously described
(23). Briefly, after preparing a single cell suspension of
splenocytes, RBC were lysed using Geys solution, T cells were
depleted by complement-mediated lysis, and high density B cells
(>1.079 g/ml) were isolated by centrifugation through a discontinuous
Percoll gradient (Amersham Pharmacia Biotech). The B lymphoma cell line
K46-17µm
(K46) was provided by Dr. Michael Reth (Max-Planck
Institut fur Immunbiologie, Frieburg, Germany). K46 cells were cultured
in IMDM supplemented with 5% FBS (HyClone, Logan, UT), 2 mM
L-glutamine, 50 µm 2-ME, 100 µg/ml
streptomycin-penicillin, and 50 µg/ml gentamicin (Sigma, St. Louis,
MO) at 37°C under 5% CO2.
Immunoprecipitation and immunoblotting
MHC class II and BCR-mediated signaling events were analyzed following stimulation of cells with the respective mAbs as described below. To analyze MHC class II mediated signaling, K46 cells were harvested and resuspended in IMDM with 5% FBS (2.5 x 107/sample). Samples were then incubated with biotinylated anti-class II mAb (D3.137.5.7, 20 µg/ml) for 15 min at room temperature. The cells were washed once in room temperature PBS, resuspended in IMDM with 5% FBS (1 ml/sample), and allowed to equilibrate for 15 min at 37°C under 5% CO2. Next, the cells were stimulated for various times with NeutrAvidin (20 µg/ml). Stimulation of cells with either anti-class II mAb or NeutrAvidin alone did not elicit a signaling response as determined by measurement of calcium mobilization (data not shown). The effect of signaling through class II was compared with that observed when cells were stimulated through the BCR (goat anti-mouse IgG/A/M F(ab')2, 5 µg/ml), or with pervanadate. For consistency, cells stimulated through the BCR or with pervanadate were handled in the same manner as those stimulated with anti-class II mAb and NeutrAvidin. After stimulation, samples were washed twice in 7 ml of ice-cold PBS and lysed in 0.5 ml of lysis buffer (25 mM HEPES, 150 mM NaCl, pH 7.8, 10 mM EDTA, 1 mM EGTA, 0.1 mM Na3V04, and 1% Nonidet P-40). Cells were lysed for 1 h on ice, and the lysates were centrifuged at 12,000 x g for 15 min at 4°C to remove debris. Lysates were precleared by incubation with protein G-Sepharose beads (Vav, PI 3-K, SHP-1, and CD19 experiments) or RG7/9.1 bound to Sepharose-4B beads (CD22 experiments) for 1 h at 4°C to minimize nonspecific protein binding. Proteins of interest were immunoprecipitated from precleared lysates either by the addition of soluble Abs followed by the addition of protein G-Sepharose beads (Vav, PI 3-K, CD19, SHP-1) or by the addition of Ab coupled directly to Sepharose 4B beads (CD22). Each immunoprecipitation step was performed for 1 h at 4°C with rotation. Immune complex-coated beads were collected and washed four times with lysis buffer containing 0.2% Nonidet P-40. The beads were resuspended in 50 µl of reducing SDS-PAGE sample buffer, boiled for 5 min, and centrifuged at 12,000 x g for 5 min.
For each condition, the proteins contained in 15 µl of SDS-PAGE sample buffer were separated on 8% acrylamide gels using SDS-PAGE and were transferred to Hybond-ECL nitrocellulose membranes. The membranes were blocked in either 3% blot qualified BSA (Promega, Madison, WI; CD22 and CD19) or 10% nonfat dry milk in TBST (Vav, PI 3-K, SHP-1) for 1 h at room temperature. The membranes were then washed five times with TBST. To detect inducible tyrosine phosphorylation of CD22 and CD19, blots were incubated with anti-phosphotyrosine (PTyr) mAb (1:3000, 4G10-HRP) for 1 h at room temperature. The blots were washed in TBST and incubated with streptavidin conjugated to HRP (1:10,000) for 1 h at room temperature. Tyrosine phosphorylation of CD19 and CD22 was visualized using enhanced chemiluminescence (ECL) according to the manufacturers instructions (Super Signal chemiluminescent substrate; Pierce). To detect binding of SHP-1 to CD22, or Vav and PI 3-K to CD19, the appropriate blots were stripped by incubating them in stripping buffer (10 mM Tris, pH 2.3, 150 mM NaCl) at 70°C for 1 h, after which they were washed repeatedly in TBST. The membranes were then blocked in 10% nonfat dry milk in TBST for 1 h at room temperature, washed extensively in TBST, and incubated with anti-SHP-1 mAb (1:250), anti-Vav Ab (1:250), or anti-PI 3-K Ab (1:300) for 1 h at room temperature. Each blot was washed in TBST and incubated with HRP-conjugated goat anti-mouse IgG (1:10,000) for 1 h at room temperature. The membranes were then washed and developed using ECL to visualize binding of effector proteins. In select CD19 experiments, membranes were stripped and reprobed with mouse anti-CD19 cytoplasmic tail mAb followed by the addition of HRP-conjugated goat anti-mouse IgG to confirm equal recovery and loading of CD19.
Measurement of calcium mobilization
Either splenic B cells or K46 cells (1 x
106/ml) were loaded with Indo-1 AM at a final
concentration of 5 µm. Indo-1-loaded cells were analyzed using a
Becton Dickinson FACSvantage flow cytometer (San Jose, CA) equipped
with an Enterprise laser from Coherent (Santa Clara, CA) set for
excitation at
364 nm at a power setting of 60 mW. Fluorescence
emissions were separated by a 505-nm short pass beam splitter into two
component emissions by passage through 405- and 485-nm centered 10-nm
band pass filters to detect violet and blue, respectively. The ratio of
emissions was calculated, and a plot was constructed of fluorescence
ratio vs time. Before analysis, cells were incubated with biotinylated
anti-class II mAb (D3.137, 5 µg/ml) for 15 min at room
temperature in the presence or absence of either biotinylated
anti-CD22 mAb (Cy34.1, 120 µg/ml) or biotinylated anti-CD19
mAb (1D3, 120 µg/ml). Additional samples were incubated with
biotinylated anti-CD19 mAb (1D3, 20 µg/ml) alone, as described
above. All samples were washed, and the baseline level of intracellular
free calcium was established. Once the baseline was measured
NeutrAvidin (20 µg/ml) was added to coligate the appropriate
receptors, after which the analysis was resumed.
Receptor-mediated desensitization assay
K46 cells (1 x 106/ml) were loaded with Indo-1 AM at a final concentration of 5 µm. Analysis of class II-mediated and/or IgM-mediated Ca2+ mobilization was performed as described previously (37). Before analysis, cells were incubated with biotinylated anti-class II mAb (D3.137, 20 µg/ml) for 15 min at room temperature, then washed. To measure BCR-mediated desensitization of class II signaling, anti-class II coated cells were analyzed using flow cytometry as previously described to establish the baseline level of intracellular free Ca2+. Once the baseline had been measured, anti-IgM mAb (B.76, 15 µg/ml) was added to the cells and the analysis resumed. After the response to BCR cross-linking had returned to baseline, NeutrAvidin (20 µg/ml) was added to the same sample. Additional samples, prepared as previously described, were analyzed to determine whether class II ligation leads to desensitization of BCR signaling. For these experiments, cells were analyzed to determine the baseline level of free intracellular Ca2+ after which they were stimulated by first cross-linking the biotinylated anti-class II mAb (D3.137.1, 20 µg/ml) with the addition of NeutrAvidin (20 µg/ml). After the response had returned to baseline, the same cells were stimulated via the addition of anti-IgM (B76, 15 µg/ml) and then analyzed immediately.
| Results |
|---|
|
|
|---|
The studies presented in this paper used the K46 B lymphoma cell
line to examine MHC class II signaling. This cell line is
representative of an activated B lymphocyte in that cross-linking of
class II leads to PTK activation and calcium mobilization in the
absence of priming signals, such as anti-Ig mAb and IL-4 (24, 25). Because signaling through class II has previously been
shown to involve the activation of effector proteins that are common to
the BCR signal transduction pathway (23, 24, 25), studies were
designed to determine whether stimulation through the BCR desensitizes
class II signaling. K46 cells loaded with the calcium-sensitive dye
Indo-1 were preincubated with biotinylated anti-class II mAb
(D3.137.1, 20 µg/ml). Next, the baseline concentration of free
intracellular Ca2+ was established for each
sample, and the cells were stimulated by the addition of anti-IgM
mAb (B76, 15 µg/ml), after which the analysis was resumed
immediately. The response to BCR cross-linking consistently generated a
large calcium flux response (Fig. 1
).
Once the response had returned to baseline, the same cells were
restimulated by the addition of NeutrAvidin to cross-link class II
receptors bound with biotinylated anti-class II mAb. Subsequent
analysis of the cells failed to detect a significant calcium
mobilization response after class II ligation. When compared with the
normal calcium mobilization response elicited by class II ligation
alone, it was clear that signaling had been attenuated by prior
cross-linking of the BCR (Fig. 1
).
|
|
|
Based on the finding that class II and the BCR exhibit the ability
to reciprocally desensitize one another, and therefore presumably use
similar signaling pathways, it was of interest to determine whether
class II signaling is regulated by coreceptors in a manner similar to
the BCR. Because CD19 and CD22 have been shown to regulate signals
transduced through the BCR in either a positive or negative manner,
respectively (33, 34, 49), experiments were conducted to
determine whether these coreceptors modulate signals transduced by
class II. K46 cells were stimulated by incubation with biotinylated mAb
against class II followed by the addition of NeutrAvidin.
Alternatively, cells were stimulated by the addition of anti-mouse
IgG/A/M polyclonal Ab to cross-link the BCR. To detect
activation-dependent phosphorylation of CD22, experiments were
performed in which CD22 was immunoprecipitated from cell lysates using
Sepharose 4B beads conjugated to anti-CD22 mAb (NIMR-6). The
resultant immune-complexes were resolved by SDS-PAGE and were analyzed
by Western blotting with an anti-phosphotyrosine mAb. Tyrosine
phosphorylation of CD22 was observed within 1 min in K46 cells
stimulated by BCR ligation (Fig. 4
).
Class II cross-linking resulted in increased protein tyrosine
phosphorylation of CD22 as well, and the response exhibited kinetics
that were similar to those for BCR-dependent phosphorylation. In
parallel experiments, cell lysates were incubated with soluble
anti-CD19 mAb, and the resultant immune-complexes were recovered by
incubation with protein G-conjugated Sepharose beads. The proteins were
resolved by SDS-PAGE and analyzed by anti-phosphotyrosine Western
blotting. As expected, CD19 isolated from K46 cells that were
stimulated through the BCR exhibited inducible tyrosine phosphorylation
(Fig. 5
). As was observed in the case of
CD22, class II cross-linking resulted in phosphorylation of CD19 on
tyrosine residues within 1 min. These results clearly demonstrate that
BCR- and class II-dependent signaling leads to comparable inducible
tyrosine phosphorylation of the coreceptors CD19 and CD22.
|
|
Previous studies have demonstrated that BCR-dependent tyrosine
phosphorylation of CD19 and CD22 plays a direct role in their function
as coreceptors through the generation of phosphotyrosine motifs in
their respective cytoplasmic domains that recruit SH2 domain-containing
effector proteins (39, 40, 41, 42, 43, 44). Thus, it was of interest to
determine whether class II-mediated phosphorylation of CD19 and CD22
promotes the recruitment of effector proteins that might be involved in
modulation of class II signaling. Toward this end, K46 cells were
stimulated either by cross-linking the BCR with polyclonal
anti-mouse Ig or with biotinylated anti-class II mAb and
NeutrAvidin for various periods of time. Subsequently, CD22 was
immunoprecipitated from cell lysates by incubation with anti-CD22
mAb conjugated to Sepharose 4B beads. The immune complexes were
resolved by SDS-PAGE and analyzed by Western blotting with
anti-phosphotyrosine mAb to confirm inducible tyrosine
phosphorylation of CD22 (Fig. 6
, upper panel). The blot was stripped and reprobed with
anti-SHP-1 mAb before the addition of goat anti-mouse Ig
secondary Ab conjugated with HRP. Tyrosine phosphorylation of CD22 in
response to BCR cross-linking resulted in the recruitment of the PTP
SHP-1 (Fig. 6
, lower panel). In parallel samples, tyrosine
phosphorylation of CD22 isolated from cells stimulated through class II
was associated with inducible recruitment of SHP-1 as well. Increased
association of SHP-1 with CD22 was detectable within 1 min in both BCR
and class II-stimulated cells; however, the interaction appeared to be
more transient in response to class II cross-linking. Thus, the
functionally relevant effector protein SHP-1 is indeed recruited to
CD22 in response to both BCR- and class II-mediated
phosphorylation.
|
|
Data obtained from the previous experiments demonstrated that
tyrosine phosphorylation of CD19 and CD22 following class II ligation
results in the recruitment of specific effector proteins that are known
to modulate signal transduction via the BCR. However, it remained to be
determined whether CD19 and CD22 could indeed affect class II signaling
through the recruitment of these effector proteins. Thus, experiments
were designed to investigate this possibility in which the effect of
coligating either CD19 or CD22 with class II was assessed by monitoring
calcium mobilization. K46 cells loaded with Indo-1 were incubated with
a suboptimal concentration of biotinylated anti-class II mAb in the
presence or absence of varying concentrations of biotinylated
anti-CD22 mAb. Unbound Ab was removed by washing and the basal
concentration of intracellular free Ca2+ was
measured. Next, the cells were stimulated by the addition of
NeutrAvidin to cross-link class II alone or to effect co-cross-linking
of CD22 and class II. Coligation of CD22 with class II resulted in a
reproducible decrease in calcium mobilization that was dependent on the
concentration of anti-CD22 mAb used when compared with the response
generated by class II ligation alone (Fig. 8
). Thus, SHP-1 recruitment by CD22
appears to exert a negative effect on class II signaling in a manner
similar to that observed for BCR signaling.
|
|
|
| Discussion |
|---|
|
|
|---|
Because class II is constitutively coupled to the PTK-dependent signaling pathway in the K46 cell line, these cells constitute a suitable model in which it is possible to test whether BCR- or class II-mediated signaling results in heterologous desensitization of the other receptor. That the BCR and class II do indeed exhibit the ability to mediate reciprocal desensitization of one another, suggests that these receptors are coupled to signaling pathways that are functionally linked and therefore share common processes and/or elements. Reciprocal desensitization was observed within 1015 min after stimulation of K46 cells through either the BCR or class II suggesting that desensitization results from alterations in receptor-proximal events. This is supported by the observation that desensitization of both the BCR and class II is associated with an inability to detect inducible protein tyrosine phosphorylation upon receptor cross-linking (data not shown).
Previous studies have shown that BCR desensitization is correlated with
uncoupling of the Ag recognition component (membrane Ig) from the
signal transducing element comprised of Ig-
and Ig-
(50). Thus, desensitization of the BCR appears to be
mediated by physical uncoupling of the receptor from intracellular
membrane-proximal effector proteins (i.e., PTKs). Structure/function
studies have demonstrated that the ability of class II to activate PTKs
and to mediate calcium mobilization is dependent on conserved regions
within the transmembrane domains of both the class II
- and
-chains (1, 25, 28, 29, 30, 31). This, in turn, suggests that
coupling of class II to intracellular effector proteins is mediated
through its association with a transmembrane intermediate transducer
element(s), analogous to the way the BCR propagates a signal through
its interaction with Ig-
/Ig-
. Thus, it is possible that
cross-linking of the BCR promotes uncoupling of class II from an
associated transducing element thereby inhibiting its ability to
propagate a signal. Conversely, transduction of a signal via class II
could result in desensitization of the BCR by causing it to dissociate
from the Ig-
/Ig-
heterodimer. Because the BCR and class II
signaling pathways appear to use common effector proteins such as Lyn
and Syk, an alternative explanation for the observed heterologous
desensitization could be due to the fact that these receptors compete
with one another for recruitment of essential effector proteins. In
conclusion, although these studies do not confirm that the BCR and
class II actually regulate the function of one another under
physiological conditions in normal B cells, they do support the
hypothesis that both receptors transduce signals via similar
mechanistic processes.
Because class II signaling appears to be mediated by a mechanism that shares numerous similarities with the BCR, it was logical to hypothesize that class II signaling may be modulated by coreceptors, as well. BCR signaling is regulated by coreceptors including CD19 and CD22, which exert opposite effects on the magnitude and duration of the signal, thereby effectively decreasing or increasing the threshold of stimulus required to drive a response, respectively. Although CD22 and CD19 play an important role in regulating BCR signaling, studies have not previously examined the possibility that either is involved in regulating signal transduction via other surface receptors expressed by the B cell. The results presented herein demonstrate that CD19 and CD22 differentially modulate class II-mediated calcium mobilization. However, the physical/functional nature of the relationship between class II and these coreceptors has yet to be elucidated from a physiological perspective. Based on the available evidence relating to class II signaling in murine B cells, CD19 and CD22 would presumably be involved in modulation of class II signaling in primed B cells in which class II is functionally coupled to the activation of PTKs, phosphoinositide hydrolysis, and Ca2+ mobilization.
CD22 is a sialoadhesin that recognizes sialic acid in the natural
structure Sia
26Gal
14GlcNAc (
2, 6-linked sialic acid)
(51, 52). Because class II is a sialylated glycoprotein it
may function as a ligand for the extracellular sailoadhesin domain of
CD22 (53, 54). As class II is constitutively sialylated,
CD22 might be important for attenuation of class II signals by virtue
of its ability to constitutively interact with class II. This would
presumably prevent aberrant activation/differentiation of primed B
cells until such time as they encounter appropriate T cell-derived
signals. B cells that have processed and presented Ag in the context of
class II could transduce a productive signal in response to class II
cross-linking by an Ag-specific CD4+ T cell if
the interaction between class II and CD22 is effectively disrupted. In
this regard, it is possible that class II may be sequestered away from
CD22 via one or more mechanisms. For example, class II has been shown
to associate with glycolipid-enriched microdomains (GEM) in response to
ligation (32) and this might physically release it from
CD22-mediated repression. It is equally possible that contact with
CD4+ T cells could promote the formation of
intercellular bonds mediated by binding of CD22 to sialylated proteins
on the T cell. For example, previous studies have demonstrated that
CD22 binds to CD45 on T cells (55, 56). The formation of
an intercellular bond between CD22 and CD45 or some other
sialoglycoprotein could conceivably displace class II from CD22 on the
B cell. Alternatively, studies have demonstrated that the expression of
2,6-sialyltransferase in B cells is cell cycle dependent and that a
B cell-specific
2,6-sialyltransferase promoter is up-regulated
during B cell activation (57, 58). Increased expression
and/or activity of
2,6-sialyltransferase in activated B cells could
lead to increased sialylation of CD22, which has been shown to inhibit
the ability of CD22 to bind to other
2,6-linked sialic acid
containing proteins (59). Alternatively, up-regulation of
2,6-sialyltransferase could promote sialylation of other surface
proteins that compete with class II for binding to CD22. The net effect
would be to disrupt the interaction between class II and CD22 thereby
potentiating class II signaling.
With regard to the interaction between class II and CD19, several studies have shown that CD81, a constituent of the CD19/CD21 multimeric signaling complex, physically interacts with class II (60, 61, 62). Through its interaction with the CD19/CD21 complex, CD81 could potentially link CD19 to class II indirectly and in this way, class II signaling could be enhanced through the recruitment of effector proteins to CD19. Although studies have shown that the interaction between class II and CD81 in resting cells involves only a limited fraction of the total cellular pool of the relevant molecules (60), CD81 and class II have nevertheless been demonstrated to undergo cocapping in response to ligation of class II (61). Thus, TCR/CD4-dependent cross-linking of class II on the surface of the B cell, leading to its recruitment into GEMs, could lead to colocalization of CD19 through the class II-CD81 interaction. The net effect would be to focus CD19 in GEMs containing PTKs, where it would be phosphorylated, thereby promoting the recruitment of positive signaling effectors such as Vav and PI 3-K that would then serve to amplify signals delivered via class II.
In conclusion, it has clearly been demonstrated that class II-mediated signals synergize with other signals received via molecules such as CD40 (63). Specifically, class II-dependent signaling enhances, in an Ag-specific manner, the responsiveness of B cells to subsequent T cell help that is provided by the nonpolymorphic binding of CD40L to CD40 (63). Thus, prior stimulation through the BCR and class II ensures that Ag-specific B cells respond preferentially to ILs and T cell help. In this regard, it would be important to ensure that aberrant class II-dependent signals cannot be propagated in primed B cells unless those cells encounter appropriate Ag-specific T helper cells. The putative constitutive interaction between class II and CD22 could in fact attenuate class II signaling in the absence of cognate T-B interactions. Conversely, CD19 may be important for potentiating class II signaling to promote B cell responsiveness to subsequent CD40-dependent signals. This would facilitate the delivery of an optimal signal that promotes B cell proliferation, differentiation and isotype switching. Because CD19 and CD22 have the potential to modulate class II signaling, it is formally possible that they play an important role not only in regulation of B cell activation, but differentiation and isotype switching as well.
| Acknowledgments |
|---|
cell line. | Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Louis B. Justement, Department of Microbiology, Division of Developmental and Clinical Immunology, 378 Wallace Tumor Institute, 1824 6th Avenue South, Birmingham, AL 35294-3300. ![]()
3 Abbreviations used in this paper: class II, MHC class II; PTP, protein tyrosine phosphatase; BCR, B cell Ag receptor; PKC, protein kinase C; PTK, protein tyrosine kinase; PLC
, phospholipase C
; IP3, 1,4,5-inositol trisphosphate; PI 3-K, phosphatidylinositol 3-kinase; ECL, enhanced chemiluminescence; GEM, glycolipid-enriched microdomain. ![]()
Received for publication April 28, 2000. Accepted for publication August 25, 2000.
| References |
|---|
|
|
|---|
and tumor necrosis factor
genes by MHC class II ligands. J. Immunol. 146:2310.[Abstract]
and PCK
II isoforms is abrogated following truncation of DR
cytoplasmic domains. J. Immunol. 159:3792.[Abstract]
chains deliver distinct signals required for MHC class II-mediated B cell activation. Immunity 3:349.[Medline]
molecule for class II-mediated B cell signaling. J. Immunol. 151:5282.[Abstract]
cytoplasmic domains reveal signaling-independent defects in antigen presentation. Int. Immunol. 7:665.
1 upon B cell activation. J. Exp. Med. 183:547.
/Ig-
: implications for receptor desensitization. Immunity 10:239.[Medline]
2,6-linked sailic acids that are required for recognition. J. Biol. Chem. 268:7019.
2,6 sialyltransferase, CD75, on B cells. Cell 66:1133.[Medline]
-galactoside
-2,6-sialyltransferase) on human B lymphocytes. Eur. J. Immunol. 22:1149.[Medline]
2,6-sialyltransferase is implicated in the regulation of CD22-mediated adhesion. J. Biol. Chem. 269:11783.This article has been cited by other articles:
![]() |
M. Rovedo and R. Longnecker Epstein-Barr Virus Latent Membrane Protein 2A Preferentially Signals through the Src Family Kinase Lyn J. Virol., September 1, 2008; 82(17): 8520 - 8528. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jin, P. M. Waterman, K. R. Jonscher, C. M. Short, N. A. Reisdorph, and J. C. Cambier MPYS, a Novel Membrane Tetraspanner, Is Associated with Major Histocompatibility Complex Class II and Mediates Transduction of Apoptotic Signals Mol. Cell. Biol., August 15, 2008; 28(16): 5014 - 5026. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Kin and V. M. Sanders CD86 Regulates IgG1 Production via a CD19-Dependent Mechanism J. Immunol., August 1, 2007; 179(3): 1516 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Nashar and J. R. Drake Dynamics of MHC Class II-Activating Signals in Murine Resting B Cells J. Immunol., January 15, 2006; 176(2): 827 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mills, J. C. Stolpa, and J. C. Cambier Cognate B Cell Signaling via MHC Class II: Differential Regulation of B Cell Antigen Receptor and MHC Class II/Ig-{alpha}{beta} Signaling by CD22 J. Immunol., January 1, 2004; 172(1): 195 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Tuscano, R. T. O'Donnell, L. A. Miers, L. A. Kroger, D. L. Kukis, K. R. Lamborn, T. F. Tedder, and G. L. DeNardo Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts Blood, May 1, 2003; 101(9): 3641 - 3647. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bouillon, Y. El Fakhry, J. Girouard, H. Khalil, J. Thibodeau, and W. Mourad Lipid Raft-dependent and -independent Signaling through HLA-DR Molecules J. Biol. Chem., February 21, 2003; 278(9): 7099 - 7107. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Knoetig, T. A. Torrey, Z. Naghashfar, T. McCarty, and H. C. Morse III CD19 Signaling Pathways Play a Major Role for Murine AIDS Induction and Progression J. Immunol., November 15, 2002; 169(10): 5607 - 5614. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-G. Castaigne, W. Guo, C. Leveille, D. Charron, and R. Al-Daccak A CD18-dependent protein kinase C {beta}-mediated alternative cell death pathway of activated monocytes Int. Immunol., September 1, 2002; 14(9): 1003 - 1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Lokshin, P. Kalinski, R. R. Sassi, R. B. Mailliard, J. Muller-Berghaus, W. J. Storkus, X. Peng, A. M. Marrangoni, R. P. Edwards, and E. Gorelik Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II Int. Immunol., September 1, 2002; 14(9): 1027 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Natarajan, N. C. Sahoo, and K. V. S. Rao Signal Thresholds and Modular Synergy During Expression of Costimulatory Molecules in B Lymphocytes J. Immunol., July 1, 2001; 167(1): 114 - 122. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |